CLEC12A and acute myeloid leukemia: We validated their cell surface expression by flow cytometry on AML cell lines and patient AML blasts, as well as on healthy-donor HSPCs and T-cells, alongside a panel of selected AML antigens, including CD38, CD123, and CD371 [37–39], Fig. S1.